NMR metabolomics of human blood and urine in disease research

Journal of Pharmaceutical and Biomedical Analysis

Volumn 93, Issue , 2014, Pages 17-26

  Duarte, Iola F ^a   Diaz, Sílvia O ^a   Gil, Ana M ^a  

^a UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

Blood; Disease; Metabolomics; NMR spectroscopy; Urine

Indexed keywords

CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILDBIRTH; DIGESTIVE SYSTEM DISEASE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; METABOLISM; METABOLOMICS; PREGNANCY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUERPERIUM; RESPIRATORY TRACT DISEASE; REVIEW; STUDY DESIGN; URINARY TRACT DISEASE; UROGENITAL TRACT DISEASE; BODY FLUID; MEDICAL RESEARCH; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES;

BIOLOGICAL MARKER;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; BODY FLUIDS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOMICS;

EID: 84900342981     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.09.025     Document Type: Review

References (130)

1. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
2. Fiehn O. Metabolomics - the link between genotypes and phenotypes. Plant Mol. Biol. 2002, 48:155-171.
3. Ebbels T.M.D., Cavill R. Bioinformatic methods in NMR-based metabolic profiling. Prog. Nucl. Magn. Reson. Spectrosc. 2009, 55:361-374.
4. Eliasson M., Rannar S., Trygg J. From data processing to multivariate validation - essential steps in extracting interpretable information from metabolomics data. Curr. Pharm. Biotechnol. 2011, 12:996-1004.
5. Bujak R., Daghir E., Rybka J., Koslinski P., Markuszewski M.J. Metabolomics in urogenital cancer. Bioanalysis 2011, 3:913-923.
6. DeFeo E.M., Wu C.-L., McDougal W.S., Cheng L.L. A decade in prostate cancer: from NMR to metabolomics. Nat. Rev. Urol. 2011, 8:301-311.
7. Ng D.J.Y., Pasikanti K.K., Chan E.C.Y. Trend analysis of metabonomics and systematic review of metabonomics-derived cancer marker metabolites. Metabolomics 2011, 7:155-178.
8. Trock B.J. Application of metabolomics to prostate cancer. Urol. Oncol. 2011, 29:572-581.
9. Van Q.N., Veenstra T.D., Issaq H.J. Metabolic profiling for the detection of bladder cancer. Curr. Urol. Rep. 2011, 12:34-40.
10. Duarte I.F., Gil A.M. Metabolic signatures of cancer unveiled by NMR spectroscopy of human biofluids. Prog. Nucl. Magn. Reson. Spectrosc. 2012, 62:51-74.
11. Griffin J.L., Atherton H., Shockcor J., Atzori L. Metabolomics as a tool for cardiac research. Nat. Rev. Cardiol. 2011, 8:630-643.
12. Senn T., Hazen S.L., Tang W.H.W. Translating metabolomics to cardiovascular biomarkers. Prog. Cardiovasc. Dis. 2012, 55:70-76.
13. Rhee E.P., Gerszten R.E. Metabolomics and cardiovascular biomarker discovery. Clin. Chem. 2012, 58:139-147.
14. Heather L.C., Wang X., West J.A., Griffin J.L. A practical guide to metabolomic profiling as a discovery tool for human heart disease. J. Mol. Cell. Cardiol. 2013, 55:2-11.
15. Friedrich N. Metabolomics in diabetes research. J. Endocrinol. 2012, 215:29-42.
16. Xie B., Waters M.J., Schirra H.J. Investigating potential mechanisms of obesity by metabolomics. J. Biomed. Biotechnol. 2012, 2012. ID 805683.
17. Pacchiarotta T., Deelder A.M., Mayboroda O.A. Metabolomic investigations of human infections. Bioanalysis 2012, 4:919-925.
18. Sitole L.J., Williams A.A., Meyer D. Metabonomic analysis of HIV-infected biofluids. Mol. Biosyst. 2013, 9:18-28.
19. Gupta A., Bansal N., Houston B. Metabolomics of urinary tract infection: a new uroscope in town. Expert Rev. Mol. Diagn. 2012, 12:361-369.
20. Weiss R.H., Kim K. Metabolomics in the study of kidney diseases. Nat. Rev. Nephrol. 2012, 8:22-33.
21. Noto A., Cibecchini F., Fanos V., Mussap M. NGAL and metabolomics: the single biomarker to reveal the metabolome alterations in kidney injury. Biomed. Res. Int. 2013, 2013. ID 612032.
22. Fanos V., Antonucci R., Barberini L., Noto A., Atzori L. Clinical application of metabolomics in neonatology. J. Matern. Fetal Neonatal Med. 2012, 25:104-109.
23. Syggelou A., Iacovidou N., Atzori L., Xanthos T., Fanos V. Metabolomics in the developing human being. Pediatr. Clin. North Am. 2012, 59:1039-1058.
24. Lutz N.W., Cozzone P.J. Metabolic profiling in multiple sclerosis and other disorders by quantitative analysis of cerebrospinal fluid using nuclear magnetic resonance spectroscopy. Curr. Pharm. Biotechnol. 2011, 12:1016-1025.
25. Hassan-Smith G., Wallace G.R., Douglas M.R., Sinclair A.J. The role of metabolomics in neurological disease. J. Neuroimmunol. 2012, 248:48-52.
26. Xu X.-H., Huang Y., Wang G., Chen S.-D. Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease. Neurosci. Bull. 2012, 28:641-648.
27. Atzei A., Atzori L., Moretti C., Barberini L., Noto A., Ottonello G., Pusceddu E., Fanos V. Metabolomics in paediatric respiratory diseases and bronchiolitis. J. Matern. Fetal Neonatal Med. 2011, 24:60-63.
28. Sofia M., Maniscalco M., de Laurentiis G., Paris D., Melck D., Motta A. Exploring airway diseases by NMR-based metabonomics: a review of application to exhaled breath condensate. J. Biomed. Biotechnol. 2011, 2011. ID 403260.
29. Adamko D.J., Sykes B.D., Rowe B.H. The metabolomics of asthma novel diagnostic potential. Chest 2012, 141:1295-1302.
30. Snowden S., Dahlen S.-E., Wheelock C.E. Application of metabolomics approaches to the study of respiratory diseases. Bioanalysis 2012, 4:2265-2290.
31. Slupsky C.M., Steed H., Wells T.H., Dabbs K., Schepansky A., Capstick V., Faught W., Sawyer M.B. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res. 2010, 16:5835-5841.
32. Gu H., Pan Z., Xi B., Asiago V., Musselman B., Raftery D. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer. Anal. Chim. Acta 2011, 686:57-63.
33. Oakman C., Tenori L., Claudino W.M., Cappadona S., Nepi S., Battaglia A., Bernini P., Zafarana E., Saccenti E., Fornier M., Morris P.G., Biganzoli L., Luchinat C., Bertini I., Di Leo A. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann. Oncol. 2011, 22:1295-1301.
34. Tenori L., Oakman C., Claudino W.M., Bernini P., Cappadona S., Nepi S., Biganzoli L., Arbushites M.C., Luchinat C., Bertini I., Di Leo A. Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Mol. Oncol. 2012, 6:437-444.
35. Stebbing J., Sharma A., North B., Athersuch T.J., Zebrowski A., Pchejetski D., Coombes R.C., Nicholson J.K., Keun H.C. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann. Oncol. 2012, 23:U860-U862.
36. Ludwig C., Ward D.G., Martin A., Viant M.R., Ismail T., Johnson P.J., Wakelam M.J.O., Guenther U.L. Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magn. Reson. Chem. 2009, 47:S68-S73.
37. Backshall A., Sharma R., Clarke S.J., Keun H.C. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin. Cancer Res. 2011, 17:3019-3028.
38. Farshidfar F., Weljie A.M., Kopciuk K., Buie W.D., MacLean A., Dixon E., Sutherland F.R., Molckovsky A., Vogel H.J., Bathe O.F. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med. 2012, 4:42.
39. Bertini I., Cacciatore S., Jensen B.V., Schou J.V., Johansen J.S., Kruhoffer M., Luchinat C., Nielsen D.L., Turano P. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. 2012, 72:356-364.
40. Chadeau-Hyam M., Athersuch T.J., Keun H.C., De Iorio M., Ebbels T.M.D., Jenab M., Sacerdote C., Bruce S.J., Holmes E., Vineis P. Meeting-in-the-middle using metabolic profiling - a strategy for the identification of intermediate biomarkers in cohort studies. Biomarkers 2011, 16:83-88.
41. Gao H., Lu Q., Liu X., Cong H., Zhao L., Wang H., Lin D. Application of H-1 NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009, 100:782-785.
42. Nahon P., Amathieu R., Triba M.N., Bouchemal N., Nault J.-C., Ziol M., Seror O., Dhonneur G., Trinchet J.-C., Beaugrand M., Le Moyec L. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin. Cancer Res. 2012, 18:6714-6722.
43. Shariff M.I.F., Ladep N.G., Cox I.J., Williams H.R.T., Okeke E., Malu A., Thillainayagam A.V., Crossey M.M.E., Khan S.A., Thomas H.C., Taylor-Robinson S.D. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J. Proteome Res. 2010, 9:1096-1103.
44. Shariff M.I.F., Gomaa A.I., Cox I.J., Patel M., Williams H.R.T., Crossey M.M.E., Thillainayagam A.V., Thomas H.C., Waked I., Khan S.A., Taylor-Robinson S.D. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J. Proteome Res. 2011, 10:1828-1836.
45. Bathe O.F., Shaykhutdinov R., Kopciuk K., Weljie A.M., McKay A., Sutherland F.R., Dixon E., Dunse N., Sotiropoulos D., Vogel H.J. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidem. Biomark. 2011, 20:140-147.
46. OuYang D., Xu J., Huang H., Chen Z. Metabolomic profiling of serum from human pancreatic cancer patients using H-1 NMR spectroscopy and principal component analysis. Appl. Biochem. Biotechnol. 2011, 165:148-154.
47. Zhang L., Jin H., Guo X., Yang Z., Zhao L., Tang S., Mo P., Wu K., Nie Y., Pan Y., Fan D. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by H-1 nuclear magnetic resonance-based metabonomic profiles. Clin. Biochem. 2012, 45:1064-1069.
48. Napoli C., Sperandio N., Lawlor R.T., Scarpa A., Molinari H., Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by H-1 nuclear magnetic resonance: identification, mapping, and evolution. J. Proteome Res. 2012, 1(1):1274-1283.
49. 1H NMR metabolic profiling of human serum associated with benign and malignant gallstone diseases. Metabolomics 2013, 9:515-528.
50. Hasim A., Ali M., Mamtimin B., Ma J.-Q., Li Q.-Z., Abudula A. Metabonomic signature analysis of cervical carcinoma and precancerous lesions in women by H-1 NMR spectroscopy. Exp. Ther. Med. 2012, 3:945-951.
51. Zhang J., Liu L., Wei S., Gowda G.A.N., Hammoud Z., Kesler K.A., Raftery D. Metabolomics study of esophageal adenocarcinoma. J. Thorac. Cardiovasc. Surg. 2011, 141:U469-U1048.
52. Zhang J., Bowers J., Liu L., Wei S., Gowda G.A.N., Hammoud Z., Raftery D. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. PLoS ONE 2012, 7:e30181.
53. Hasim A., Ma H., Mamtimin B., Abudula A., Niyaz M., Zhang L.-w., Anwer J., Sheyhidin I. Revealing the metabonomic variation of EC using H-1-NMR spectroscopy and its association with the clinicopathological characteristics. Mol. Biol. Rep. 2012, 39:8955-8964.
54. Rocha C.M., Carrola J., Barros A.S., Gil A.M., Goodfellow B.J., Carreira I.M., Bernardo J., Gomes A., Sousa V., Carvalho L., Duarte I.F. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J. Proteome Res. 2011, 10:4314-4324.
55. Lodi A., Tiziani S., Khanim F.L., Guenther U.L., Viant M.R., Morgan G.J., Bunce C.M., Drayson M.T. Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease. PLoS ONE 2013, 8:e56422.
56. Tiziani S., Lopes V., Gunther U.L. Early stage diagnosis of oral cancer using H-1 NMR-based metabolomics. Neoplasia 2009, 11. 269-U269.
57. Zhou J., Xu B., Huang J., Jia X., Xue J., Shi X., Xiao L., Li W. H-1 NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma. Clin. Chim. Acta 2009, 401:8-13.
58. Garcia E., Andrews C., Hua J., Kim H.L., Sukumaran D.K., Szyperski T., Odunsi K. Diagnosis of early stage ovarian cancer by H-1 NMR metabonomics of serum explored by use of a microflow NMR probe. J. Proteome Res. 2011, 10:1765-1771.
59. Fan Y., Murphy T.B., Byrne J.C., Brennan L., Fitzpatrick J.M., Watson R.W.G. Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J. Proteome Res. 2011, 10:1361-1373.
60. Gao H., Dong B., Liu X., Xuan H., Huang Y., Lin D. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal. Chim. Acta 2008, 624:269-277.
61. 1H NMR spectroscopy. Cancer Biomark. 2010, 6:11-20.
62. Carrola J., Rocha C.M., Barros A.S., Gil A.M., Goodfellow B.J., Carreira I.M., Bernardo J., Gomes A., Sousa V., Carvalho L., Duarte I.F. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J. Proteome Res. 2011, 10:221-230.
63. Williams H.R.T., Willsmore J.D., Cox I.J., Walker D.G., Cobbold J.F.L., Taylor-Robinson S.D., Orchard T.R. Serum metabolic profiling in inflammatory bowel disease. Dig. Dis. Sci. 2012, 57:2157-2165.
64. 1H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J. Proteome Res. 2012, 1(1):3344-3357.
65. Williams H.R.T., Cox I.J., Walker D.G., North B.V., Patel V.M., Marshall S.E., Jewell D.P., Ghosh S., Thomas H.J.W., Teare J.P., Jakobovits S., Zeki S., Welsh K.I., Taylor-Robinson S.D., Orchard T.R. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am. J. Gastroenterol. 2009, 104:1435-1444.
66. Bjerrum J.T., Nielsen O.H., Hao F., Tang H., Nicholson J.K., Wang Y., Olsen J. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J. Proteome Res. 2010, 9:954-962.
67. Stephens N.S., Siffledeen J., Su X., Murdoch T.B., Fedorak R.N., Slupsky C.M. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J. Crohns Colitis 2013, 7:e42-e48.
68. Amathieu R., Nahon P., Triba M., Bouchemal N., Trinchet J.-C., Beaugrand M., Dhonneur G., Le Moyec L. Metabolomic approach by H-1 NMR spectroscopy of serum for the assessment of chronic liver failure in patients with cirrhosis. J. Proteome Res. 2011, 10:3239-3245.
69. Qi S.-W., Tu Z.-G., Peng W.-J., Wang L.-X., Xin O.-Y., Cai A.-J., Dai Y. H-1 NMR-based serum metabolic profiling in compensated and decompensated cirrhosis. World J. Gastroenterol. 2012, 18:285-290.
70. 1H NMR-based metabonomics. Hepatol. Res. 2012, 42:677-685.
71. Bertini I., Calalbro A., De Carli V., Luchinat C., Nepi S., Porfirio B., Renzi D., Saccenti E., Tenori L. The metabonomic signature of celiac disease. J. Proteome Res. 2009, 8:170-177.
72. Bernini P., Bertini I., Calabro A., la Marca G., Lami G., Luchinat C., Renzi D., Tenori L. Are patients with potential celiac disease really potential? The answer of metabonomics. J. Proteome Res. 2011, 10:714-721.
73. Wu Q., Zhang Q., Sun B., Yan X., Tang Y., Qiao X., Chen Q., Yu S., Liang F. H-1 NMR-based metabonomic study on the metabolic changes in the plasma of patients with functional dyspepsia and the effect of acupuncture. J. Pharm. Biomed. Anal. 2010, 51:698-704.
74. 1H-NMR metabolomics can distinguish pancreatitis patients from healthy controls. JOP 2013, 14:161-170.
75. Makinen V.P., Soininen P., Forsblom C., Parkkonen M., Ingman P., Kaski K., Groop P.H., Ala-Korpela M., FinnDiane Study G. H-1 NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol. Syst. Biol. 2008, 4:167.
76. Mäkinen V.-P., Tynkkynen T., Soininen P., Peltola T., Kangas A.J., Forsblom C., Thorn L.M., Kaski K., Laatikainen R., Ala-Korpela M., Groop P.-H. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane study). J. Proteome Res. 2011, 11:1782-1790.
77. Makinen V.-P., Tynkkynen T., Soininen P., Forsblom C., Peltola T., Kangas A.J., Groop P.-H., Ala-Korpela M. Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane study). Metabolomics 2012, 8:369-375.
78. Brugnara L., Vinaixa M., Murillo S., Samino S., Angel Rodriguez M., Beltran A., Lerin C., Davison G., Correig X., Novials A. Metabolomics approach for analyzing the effects of exercise in subjects with type 1 diabetes mellitus. PLoS ONE 2012, 7:e40600.
79. Zhang X., Wang Y., Hao F., Zhou X., Han X., Tang H., Ji L. Human serum metabonomic analysis reveals progression axes for glucose intolerance and insulin resistance statuses. J. Proteome Res. 2009, 8:5188-5195.
80. Nicolescu A., Dolenko B., Bezabeh T., Stefan L.-I., Ciurtin C., Kovacs E., Smith I.C.R., Simionescu B.C., Deleanu C. Diagnosis of type II diabetes based on non-glucose regions of H-1 NMR spectra of urine: a metabonomic approach. Rev. Chim. Buchar. 2011, 62:1150-1153.
81. Qiu Y., Rajagopalan D., Connor S., Damian D., Zhu L., Handzel A., Hu G., Amanullah A., Bao S., Woody N., MacLean D., Lee K., Vanderwall D., Ryan T. Multivariate classification analysis of metabolomic data for candidate biomarker discovery in type 2 diabetes mellitus. Metabolomics 2008, 4:337-346.
82. Sun L., Hu W., Liu Q., Hao Q., Sun B., Zhang Q., Mao S., Qiao J., Yan X. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J. Proteome Res. 2012, 11:2937-2946.
83. Atiomo W., Daykin C.A. Metabolomic biomarkers in women with polycystic ovary syndrome: a pilot study. Mol. Hum. Reprod. 2012, 18:546-553.
84. Vinaixa M., Angel Rodriguez M., Samino S., Diaz M., Beltran A., Mallol R., Blade C., Ibanez L., Correig X., Yanes O. Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. PLoS ONE 2011, 6:e29052.
85. Pathmasiri W., Pratt K.J., Collier D.N., Lutes L.D., McRitchie S., Sumner S.C.J. Integrating metabolomic signatures and psychosocial parameters in responsivity to an immersion treatment model for adolescent obesity. Metabolomics 2012, 8:1037-1051.
86. Sui W., Li L., Che W., Zuo G., Chen J., Li W., Dai Y. A proton nuclear magnetic resonance-based metabonomics study of metabolic profiling in immunoglobulin a nephropathy. Clinics 2012, 67:363-373.
87. 1H NMR-based metabolic profiling of urine from children with nephrouropathies. Front. Biosci. (Elite Ed.) 2010, 2:725-732.
88. Mantle P., Modalca M., Nicholls A., Tatu C., Tatu D., Toncheva D. Comparative H-1 NMR metabolomic urinalysis of people diagnosed with Balkan endemic nephropathy, and healthy subjects, in Romania and Bulgaria: a pilot study. Toxins 2011, 3:815-833.
89. 1H-NMR-spectroscopy. Clin. Transl. Sci. 2012, 5:379-385.
90. Atzori L., Mussap M., Noto A., Barberini L., Puddu M., Coni E., Murgia F., Lussu M., Fanos V. Clinical metabolomics and urinary NGAL for the early prediction of chronic kidney disease in healthy adults born ELBW. J. Matern. Fetal Neonatal Med. 2011, 24:41-44.
91. Nevedomskaya E., Pacchiarotta T., Artemov A., Meissner A., van Nieuwkoop C., van Dissel J.T., Mayboroda O.A., Deelder A.M. H-1 NMR-based metabolic profiling of urinary tract infection: combining multiple statistical models and clinical data. Metabolomics 2012, 8:1227-1235.
92. Dong B., Jia J., Hu W., Chen Q., Jiang C., Pan J., Huang Y., Xue W., Gao H. Application of H-1 NMR metabonomics in predicting renal function recoverability after the relief of obstructive uropathy in adult patients. Clin. Biochem. 2013, 46:346-353.
93. Dutta M., Joshi M., Srivastava S., Lodh I., Chakravarty B., Chaudhury K. A metabonomics approach as a means for identification of potential biomarkers for early diagnosis of endometriosis. Mol. Biosyst. 2012, 8:3281-3287.
94. Barba I., de Leon G., Martin E., Cuevas A., Aguade S., Candell-Riera J., Barrabes J.A., Garcia-Dorado D. Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn. Reson. Med. 2008, 60:27-32.
95. Bodi V., Sanchis J., Morales J.M., Marrachelli V.G., Nunez J., Forteza M.J., Chaustre F., Gomez C., Mainar L., Minana G., Rumiz E., Husser O., Noguera I., Diaz A., Moratal D., Carratala A., Bosch X., Llacer A., Chorro F.J., Vina J.R., Monleon D. Metabolomic profile of human myocardial ischemia by Nuclear Magnetic Resonance spectroscopy of peripheral blood serum: a translational study based on transient coronary occlusion models. J. Am. Coll. Cardiol. 2012, 59:1629-1641.
96. Teul J., Ruperez F.J., Garcia A., Vaysse J., Balayssac S., Gilard V., Malet-Martino M., Luis Martin-Ventura J., Miguel Blanco-Colio L., Tunon J., Egido J., Barbas C. Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and H-1 NMR fingerprints. J. Proteome Res. 2009, 8:5580-5589.
97. Ruperez F.J., Ramos-Mozo P., Teul J., Martinez-Pinna R., Garcia A., Malet-Martino M., Camafeita E., Antonio Lopez J., Pastor-Vargas C., Egido J., Balayssac S., Gilard V., Barbas C., Luis Martin-Ventura J. Metabolomic study of plasma of patients with abdominal aortic aneurysm. Anal. Bioanal. Chem. 2012, 403:1651-1660.
98. Jung J.Y., Lee H.-S., Kang D.-G., Kim N.S., Cha M.H., Bang O.-S., Ryu D.H., Hwang G.-S. H-1-NMR-based metabolomics study of cerebral infarction. Stroke 2011, 42:1282-1288.
99. Kang S.-M., Park J.-C., Shin M.-J., Lee H., Oh J., Ryu D.H., Hwang G.-S., Chung J.H. H-1 nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clin. Biochem. 2011, 44:293-299.
100. Bernini P., Bertini I., Luchinat C., Tenori L., Tognaccini A. The cardiovascular risk of healthy individuals studied by NMR metabonomics of plasma samples. J. Proteome Res. 2011, 10:4983-4992.
101. Wurtz P., Soininen P., Kangas A.J., Makinen V.-P., Groop P.-H., Savolainen M.J., Juonala M., Viikari J.S., Kahonen M., Lehtimaki T., Raitakari O.T., Ala-Korpela M. Characterization of systemic metabolic phenotypes associated with subclinical atherosclerosis. Mol. Biosyst. 2011, 7:385-393.
102. Inouye M., Ripatti S., Kettunen J., Lyytikainen L.-P., Oksala N., Laurila P.-P., Kangas A.J., Soininen P., Savolainen M.J., Viikari J., Kahonen M., Perola M., Salomaa V., Raitakari O., Lehtimaki T., Taskinen M.-R., Jaervelin M.-R., Ala-Korpela M., Palotie A., de Bakker P.I.W. Novel loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet. 2012, 8:e1002907.
103. Yap I.K.S., Brown I.J., Chan Q., Wijeyesekera A., Garcia-Perez I., Bictash M., Loo R.L., Chadeau-Hyam M., Ebbels T., Iorio M.D., Maibaum E., Zhao L., Kesteloot H., Daviglus M.L., Stamler J., Nicholson J.K., Elliott P., Holmes E. Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study. J. Proteome Res. 2010, 9:6647-6654.
104. Tukiainen T., Tynkkynen T., Makinen V.P., Jylanki P., Kangas A., Hokkanen J., Vehtari A., Grohn O., Hallikainen M., Soininen H., Kivipelto M., Groop P.H., Kaski K., Laatikainen R., Soininen P., Pirttila T., Ala-Korpela M. A multi-metabolite analysis of serum by H-1 NMR spectroscopy: early systemic signs of Alzheimer's disease. Biochem. Biophys. Res. Commun. 2008, 375:356-361.
105. Ahmed S.S.S.J., Santosh W., Kumar S., Christlet H.T.T. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci. 2009, 16:63.
106. Sinclair A.J., Viant M.R., Ball A.K., Burdon M.A., Walker E.A., Stewart P.M., Rauz S., Young S.P. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases - a diagnostic tool?. NMR Biomed. 2010, 23:123-132.
107. Mehrpour M., Kyani A., Tafazzoli M., Fathi F., Joghataie M.-T. A metabonomics investigation of multiple sclerosis by nuclear magnetic resonance. Magn. Reson. Chem. 2013, 51:102-109.
108. Sussulini A., Prando A., Maretto D.A., Poppi R.J., Tasic L., Muller Banzato C.E., Zezzi Arruda M.A. Metabolic profiling of human blood serum from treated patients with bipolar disorder employing H-1 NMR spectroscopy and chemometrics. Anal. Chem. 2009, 81:9755-9763.
109. Zheng P., Gao H.C., Li Q., Shao W.H., Zhang M.L., Cheng K., Yang D.Y., Fan S.H., Chen L., Fang L., Xie P. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J. Proteome Res. 2012, 11:1741-1748.
110. Zheng P., Wang Y., Chen L., Yang D., Meng H., Zhou D., Zhong J., Lei Y., Melgiri N.D., Xie P. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol. Cell. Proteomics 2013, 12:207-214.
111. Cai H.-L., Li H.-D., Yan X.-Z., Sun B., Zhang Q., Yan M., Zhang W.-Y., Jiang P., Zhu R.-H., Liu Y.-P., Fang P.-F., Xu P., Yuan H.-Y., Zhang X.-H., Hu L., Yang W., Ye H.-S. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone. J. Proteome Res. 2012, 11:4338-4350.
112. Yang J., Chen T., Sun L., Zhao Z., Qi X., Zhou K., Cao Y., Wang X., Qiu Y., Su M., Zhao A., Wang P., Yang P., Wu J., Feng G., He L., Jia W., Wan C. Potential metabolite markers of schizophrenia. Mol. Psychiatr. 2013, 18:67-78.
113. Ubhi B.K., Riley J.H., Shaw P.A., Lomas D.A., Tal-Singer R., MacNeee W., Griffin J.L., Connor S.C. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur. Respir. J. 2012, 40:345-355.
114. Rodriguez D.A., Alcarraz-Vizan G., Diaz-Moralli S., Reed M., Gomez F.P., Falciani F., Guenther U., Roca J., Cascante M. Plasma metabolic profile in COPD patients: effects of exercise and endurance training. Metabolomics 2012, 8:508-516.
115. Jung J., Kim S.H., Lee H.S., Choi G.S., Jung Y.S., Ryu D.H., Park H.S., Hwang G.S. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. Clin. Exp. Allergy 2013, 43:425-433.
116. Saude E.J., Skappak C.D., Regush S., Cook K., Ben-Zvi A., Becker A., Moqbel R., Sykes B.D., Rowe B.H., Adamko D.J. Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J. Allergy Clin. Immun. 2011, 127:757-764.e756.
117. Slupsky C.M., Rankin K.N., Fu H., Chang D., Rowe B.H., Charles P.G.P., McGeer A., Low D., Long R., Kunimoto D., Sawyer M.B., Fedorak R.N., Adamko D.J., Saude E.J., Shah S.L., Marrie T.J. Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profile. J. Proteome Res. 2009, 8:5550-5558.
118. Bahado-Singh R.O., Akolekar R., Mandal R., Dong E., Xia J., Kruger M., Wishart D.S., Nicolaides K. First trimester metabolomic detection of late-onset preeclampsia. Am. J. Obstet. Gynecol. 2012, 208:58.e1-58.e7.
119. Bahado-Singh R.O., Akolekar R., Mandal R., Dong E., Xia J., Kruger M., Wishart D.S., Nicolaides K. Metabolomics and first-trimester prediction of early-onset preeclampsia. J. Matern. Fetal Neonatal Med. 2012, 25:1840-1847.
120. Sachse D., Sletner L., Mørkrid K., Jenum A.K., Birkeland K.I., Rise F., Piehler A.P., Berg J.P. Metabolic changes in urine during and after pregnancy in a large, multiethnic population-based cohort study of gestational diabetes. PLoS ONE 2012, 7:e52399.
121. Diaz S.O., Pinto J., Graça G., Duarte I.F., Barros A.S., Galhano E., Pita C., Almeida M.C., Goodfellow B.J., Carreira I.M., Gil A.M. Metabolic biomarkers of prenatal disorders: an exploratory NMR metabonomics study of second trimester maternal urine and blood plasma. J. Proteome Res. 2011, 10:3732-3742.
122. Graça G., Diaz S.O., Pinto J., Barros A.S., Duarte I.F., Goodfellow B.J., Galhano E., Pita C., Almeida M.C., Carreira I.M., Gil A.M. Can biofluids metabolic profiling help to improve healthcare during pregnancy?. Spectrosc.: Int. J. 2012, 27:515-523.
123. Tea I., Le Gall G., Kuster A., Guignard N., Alexandre-Gouabau M.-C., Darmaun D., Robins R.J. H-NMR-based metabolic profiling of maternal and umbilical cord blood indicates altered materno-foetal nutrient exchange in preterm infants. PLoS ONE 2012, 7:e29947.
124. 1H NMR-based metabolomic analysis of urine from preterm and term neonates. Front. Biosci. (Elite Ed.) 2011, 3:1005-1012.
125. Dessì A., Atzori L., Noto A., Adriaan Visser G.H., Gazzolo D., Zanardo V., Barberini L., Puddu M., Ottonello G., Atzei A., Magistris A.D., Lussu M., Murgia F., Fanos V. Metabolomics in newborns with intrauterine growth retardation (IUGR): urine reveals markers of metabolic syndrome. J. Matern. Fetal Neonatal Med. 2011, 24:35-39.
126. Godoy M.M.G., Lopes E.P.A., Silva R.O., Hallwass F., Koury L.C.A., Moura I.M., Goncalves S.M.C., Simas A.M. Hepatitis C virus infection diagnosis using metabonomics. J. Viral Hepat. 2010, 17:854-858.
127. Munshi S.U., Taneja S., Bhavesh N.S., Shastri J., Aggarwal R., Jameel S. Metabonomic analysis of hepatitis E patients shows deregulated metabolic cycles and abnormalities in amino acid metabolism. J. Viral Hepat. 2011, 18:E591-E602.
128. 1H NMR and MRS data from different biofluids and tissues enhances recovery of biological information from individuals with HIV-1 infection. J. Proteome Res. 2011, 10:1737-1745.
129. Sengupta A., Ghosh S., Basant A., Malusare S., Johri P., Pathak S., Sharma S., Sonawat H.M. Global host metabolic response to Plasmodium vivax infection: a H-1 NMR based urinary metabonomic study. Malar. J. 2011, 10:384.
130. Balog C.I.A., Meissner A., Goraler S., Bladergroen M.R., Vennervald B.J., Mayboroda O.A., Deelder A.M. Metabonomic investigation of human Schistosoma mansoni infection. Mol. Biosyst. 2011, 7:1473-1480.